Huadong Medicine Co Ltd
SZSE:000963
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.38
41.46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Huadong Medicine Co Ltd
Huadong Medicine Co Ltd
Net Income (Common)
Huadong Medicine Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Net Income (Common)
¥3.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
4%
|
CAGR 10-Years
17%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Net Income (Common)
¥8.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Net Income (Common)
¥4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
5%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Net Income (Common)
¥2.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Net Income (Common)
¥2.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
17%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Net Income (Common)
¥1.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
Huadong Medicine Co Ltd
Glance View
Huadong Medicine Co., Ltd., established in 1995, has emerged as a pivotal player within China's rapidly evolving pharmaceutical landscape. With a robust portfolio that includes innovative cancer treatments, cardiovascular drugs, and biologics, the company focuses on both research and development and the commercialization of high-quality therapeutics. Backed by cutting-edge production facilities and a strong commitment to adhering to international regulatory standards, Huadong not only serves the domestic market but also aspires to extend its reach globally. As the demand for effective healthcare solutions grows, Huadong's strategic alliances and collaborations with research institutions highlight its dedication to staying at the forefront of medical advancements. For investors, Huadong Medicine represents a well-rounded opportunity fueled by a consistent growth trajectory and a commitment to expanding its market presence. The company's focus on high-margin specialty drugs and biologics positions it favorably within the competitive landscape, catering to the increasing prevalence of chronic diseases. With a stable revenue generation model, strong management team, and innovative pipeline, Huadong Medicine is uniquely poised to capture market share and enhance shareholder value in an industry that is increasingly driven by innovation and patient-centric solutions. Investors looking to diversify into the healthcare sector, especially within the growing Asian market, may find Huadong Medicine an attractive addition to their portfolios.
See Also
What is Huadong Medicine Co Ltd's Net Income (Common)?
Net Income (Common)
3.2B
CNY
Based on the financial report for Sep 30, 2024, Huadong Medicine Co Ltd's Net Income (Common) amounts to 3.2B CNY.
What is Huadong Medicine Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
17%
Over the last year, the Net Income (Common) growth was 19%. The average annual Net Income (Common) growth rates for Huadong Medicine Co Ltd have been 11% over the past three years , 4% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
